Omeros announced that the FDA has granted OMS824 Orphan Drug Designation for the treatment of Huntington’s disease. OMS824 selectively inhibits phosphodiesterase 10 (PDE10), an enzyme found in areas of the brain linked to a wide range of diseases that affect cognition, including Huntington’s disease and schizophrenia.
Phase 1 clinical results in healthy subjects demonstrated that OMS824 is well tolerated and suggested that it has a better clinical therapeutic index or “safety factor” than other PDE10 inhibitors in development.
Omeros plans to begin a Phase 2 clinical trial evaluating OMS824 in patients with Huntington’s disease later this year. A Phase 2 clinical trial of the drug is already underway in patients with schizophrenia.
For more information call (206) 676-5000 or visit Omeros.com.